Jonathan Schimmel is the Chief Executive Officer of S2 Genomics. Jonathan brings more than 20 years of leadership experience in life science tools companies developing high performing Commercial teams.
In addition to serving as CEO of S2 Genomics, Jonathan is the founder and managing partner of Macatawa Capital, a biotech tools and molecular diagnostics focused family office. Jonathan is also a member of Life Science Angels, a Palo Alto based angel investment group, a member of Berkley SkyDeck Advisors, and on the advisory board for Tufts University Graduate School of Biomedical Sciences.
Previously, Jonathan was VP of Global Support and Sales Operations for 10x Genomics. In this role he was a foundational commercial leader, providing executive leadership in many aspects of 10x’s commercial operations. Jonathan was directly responsible for creating the support strategy and global support organization, including Global Order Management. Additionally, Jonathan was responsible for creating the initial Asia Pacific distributor strategy and subsequent leadership of the team.
Prior to 10x Genomics, Jonathan was President of Seegene Technologies, responsible for leading the commercialization of Seegene’s innovative Multiplex PCR technologies in the US market. Earlier, Jonathan held multiple senior level roles with Bio-Rad Laboratories, including Manager of Customer Operations (Order Management, Technical Support and Service), Manager of Group Marketing (Marketing Operations), finally culminating as the Vice-President and General Manager of the Gene Expression Division. In his time at Bio-Rad, Jonathan provided strategic direction for product concept, development and launch, global strategic marketing direction, and direct accountability for the R&D and marketing budgets. The product areas within his division included: PCR, Real Time PCR (hardware and reagents), Digital PCR Marketing and Commercialization in partnership with the acquired team from QuantaLife, DNA Electrophoresis, DNA Transfection, Cell Counting, Imaging, and Cell Sorting.
Jonathan holds a BS in Biology from Michigan State University and a PhD in Molecular Biology from Tufts University Graduate School of Biomedical Sciences.
Stevan Jovanovich, Ph.D.
Founder & CTO | Chairman of the Board
Dr. Stevan Jovanovich is the CTO, Founder, and Chairman of the Board of S2 Genomics, Inc. He founded S2 Genomics in 2016 to develop integrated sample preparation systems for genomics focusing on tissue samples. Previously, he was President/CEO/Founder of Silicon Valley Scientific, Inc., a spinout of Amersham Biosciences, and a Founder, CEO, and CTO of IntegenX, Inc., a Silicon Valley Scientific, Inc. spinout. IntegenX is the global leader in rapid human identification and now part of ThermoFisher. Dr. Jovanovich is a co-founder and Director of Functional Biosciences, Inc., a leading CLIA DNA sequencing laboratory.
Previous position include Vice President of Global Research at Amersham Biosciences, Science Director at Amersham Biosciences Sunnyvale, Manager of Advanced Research at Molecular Dynamics, Staff Scientist at Lawrence Berkeley National Laboratory, and Director of Microbiology at AbTox Inc.
He is author of 28 peer-reviewed papers and reviews, an inventor on over 100 US patents, and has automated life science workflows since 1987. He holds Bachelor of Science degrees in Physics and Life Sciences from MIT, a Ph.D. in Microbiology from the University of California at Davis with a minor in Molecular Biology, and a Certificate in Object-Oriented Programming from the University of California Santa Cruz Extension.
Anup Parikh, Ph.D.
As an Operating Partner at BroadOak Capital Partners, Dr. Parikh specializes in steering the firm’s initiatives within the molecular biology segment. His strategic oversight extends to several key enterprises in the life sciences field, where he serves as a board member at S2 Genomics and seqWell, as well as a board observer at Phenovista and NanoCellect.
Anup Parikh has dedicated over 15 years to the commercialization of innovative technologies that have had a substantial impact on the Biopharma, Life Sciences, and Diagnostics industries. Before joining BroadOak Capital Partners, Anup held product strategy positions at several prominent companies, including Mission Bio, 10x Genomics, and Ion Torrent. His strategic vision and execution have been instrumental in successfully launching over 50 products, encompassing a wide range of tools such as new instrumentation, kits, and analysis software.
Anup received his Ph.D. from Baylor College of Medicine in Structural and Computational Biology.
Brad Crutchfield brings nearly 40 years of experience in developing and commercializing Life Science tools. Most recently he served as the Chief Commercial Officer of 10x Genomics, building the global commercial organization to a team of 500 FTE’s which drove the growth of 10x Genomics to a $500M business. Additionally, he worked closely with the CEO of 10x Genomics to support the 2019 IPO.
Prior positions include QIAGEN’s Senior Vice President, Life Sciences business area, Vice President and General Manager, EMEA for Illumina, and positions of increasing responsibility with Bio-Rad Laboratories including 14 years as President of the Life Science Group.
Brad currently serves on the Board of Directors for Pixelgen AB and Partillion Inc., as well as an advisor for Alamar Biosciences. He earned a Bachelor of Science in Physiology from the University of California, Davis.
Michael J. Finney, Ph.D.
Dr. Finney is a board director or advisor to multiple biotechnology companies, with an emphasis on companies that supply fundamental technologies. He currently serves on the board of directors of 7 privately held companies, plus one public company, Vaxart (VXRT), where he also served as CEO for two years. He co-founded and serves on the board of The Genome Partnership, a nonprofit that runs AGBT, the leading annual conference on genomic technology. Previously, he co-founded MJ Research, a manufacturer of instruments used in genomic technology. The bootstrapped company was sold to Bio-Rad in 2004.
Anne DeGheest pioneered the HealthTech or Digital Health space as a healthcare executive, an entrepreneur, angel investor, corporate advisor and mentor capitalist. She is the founder of HealthTech Capital and MedStars.
Since she founded MedStars in 1986, she has been a corporate development advisor to large healthcare companies and a mentor capitalist specializing in investing and mentoring early-stage companies in healthcare. Her life science portfolio companies have grown into major disruptive companies that have generated over $18 billion in market value. Anne founded in 2010 HealthTech Capital, a group of private investors dedicated to funding and mentoring new “HealthTech” startups to decrease healthcare cost and empower patients.
MBA from Harvard and a Master in Business Engineering from University of Brussels.